3.62
+2.26%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Median Technologies
Its shares trade on Euronext Paris under the ticker ALMDT.PA. It has been listed since 20 May 2011. In the fiscal year to 31 December 2025, it reported revenue of €23.4m and a net loss of €34.1m. At that date it held total assets of €35.9m and shareholders' equity of −€35.2m.
MEDIAN Technologies SA engages in the development and market of software publishing solutions and provision of services in the field of medical imaging in oncology. The company is headquartered in Valbonne, Paca. The company went IPO on 2011-05-20. The firm develops lesion management solutions (LMS) to objectively measure and track cancerous or suspicious lesions, distribute a standardized oncologic report and centralize the lesion information for multidisciplinary review. The LMS line includes such products as LMS-Lung, a clinical application for the detection, evaluation and follow-up of lesions identified in CT images covering the chest; LMS-Track, a clinical application for the follow-up of oncology patients; and LMS-Liver, a clinical application for the initial evaluation and the follow-up of liver metastases and any other lesions identified in CT images covering the liver. The firm operates one subsidiary, Median Technologies Inc, based in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 20 May 2011
- Employees
- 76
- Website
- mediantechnologies.com ↗
Leadership
Pay as last reported
- Mr. Oran E. MudurogluChairman of the Board, since 2008€10,000
- Mr. Fredrik BragChief Executive Officer, Founder, Director, since 2008€562,000
- Mr. Jean-Christophe MontignyChief Financial Officer
- Mr. Thomas BonnefontChief Operating Officer & Chief Commercial Officer - Eyonis
- Mr. Nicolas DanoChief Operating Officer - iCRO
- Ms. Chrystel BrunChief Human Resources Officer
- Dr. Kapil DhingraDirector
- Mr. Timothy John HainesDirector
- Mr. Ben McdonaldDirector
- Dr. Oern StugeDirector
- Mr. Emmanuelle LeyguesIR Contact Officer, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Median Technologies SA has a strong expertise in medical imaging analysis, particularly in oncology.
- The company possesses advanced technology that allows for the efficient and accurate analysis of medical images.
- Median Technologies SA has a diverse client base, including pharmaceutical companies, hospitals, and research institutions, which provides stability and opportunities for growth.
- The company has established partnerships with key industry players, allowing for collaborations and knowledge sharing.
Weaknesses
- Median Technologies SA is heavily dependent on the success of its imaging analysis software, making it vulnerable to potential technological failures or disruptions.
- The company may face challenges in scaling its operations to meet increasing demand, particularly in terms of recruiting and training qualified personnel.
- There is a risk of potential legal and regulatory hurdles related to the use and analysis of medical imaging data, which could impact the company's operations.
Opportunities
- There is a growing demand for advanced medical imaging analysis solutions, driven by the increasing prevalence of complex diseases such as cancer.
- The company can expand its market reach by establishing partnerships with more pharmaceutical companies, hospitals, and research institutions.
- Median Technologies SA can explore opportunities in emerging markets, where there is an increasing focus on improving healthcare infrastructure.
Threats
- The competition in the medical imaging analysis industry is intense, and the company may face threats from established players and emerging startups.
- Rapid technological advancements in the field may render the company's current solutions outdated, requiring continuous investment in research and development.
- Economic downturns and budget constraints within healthcare systems can impact the company's sales and growth opportunities.
- Changing regulations and reimbursement policies may affect the adoption and utilization of the company's products and services.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.